The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy

• DOI: 10.1093/jrr/rrt235
• Publication Date: 2014-02-20T02:22:52Z
• Authors: Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Somjai Dangprasert; Chomporn Sitathanee; Parmon Puddhikarant; Chuleeporn Jiarpi...; Rawee Ruangkancha...; Patchareporn Dech...; Kumutinee Pairat
• Keywords: Cyberknife

Recent publications have reported stereotactic radiosurgery as an effective and safe treatment for intracranial hemangioblastomas. However, because of the low incidence these particular tumors, reports on large patient number studies not yet been available. The objective this study was to analyze clinical results 14 patients with 56 hemangioblastomas treated linear accelerator (linac)-based (SRS) radiotherapy (SRT) in same institute. median age 41 years (range, 28–73 years). Nine (64%) had von Hippel-Lindau disease. A total 39 lesions (70%) were CyberKnife (CK), 17 (30%) X-Knife. pretreatment volume 0.26 cm3 0.026–20.4 cm3). marginal dose 20 Gy 10–32 Gy) 1 fraction 1–10 fractions). follow-up time 24 months 11–89 months). At last follow-up, 47 tumors (84%) stable, 7 (13%) decreased 2 (4%) increased. 1-, 2- 6-year local control rates 98%, 88% 73%, respectively. No radiation complications observed study. There a trend toward failure only cystic but found be statistically significant. SRS/SRT achieved high rate without radiation-induced complications.